五洲医疗(301234) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was CNY 128,498,738.52, a decrease of 1.51% compared to the same period last year[7]. - Net profit attributable to shareholders decreased by 36.39% to CNY 7,994,259.30, while the year-to-date net profit decreased by 46.09% to CNY 18,509,389.16[7]. - Basic and diluted earnings per share both fell by 36.36% to CNY 0.1176[7]. - Total operating revenue for the current period reached ¥345,417,868.30, a slight increase from ¥342,595,211.54 in the previous period, representing a growth of approximately 0.84%[24]. - Operating profit for the current period was ¥23,479,459.16, down from ¥40,874,703.36 in the previous period, indicating a decline of approximately 42.4%[24]. - The total profit for the current period is ¥18,509,389.16, a decrease of 46.0% compared to ¥34,335,329.36 in the previous period[25]. - The net profit attributable to the parent company's shareholders is ¥18,509,389.16, reflecting a 46.0% decline from ¥34,335,329.36 year-over-year[25]. - The basic and diluted earnings per share for the current period are both ¥0.2722, down from ¥0.5049 in the previous period, representing a 46.0% decrease[25]. - The company’s total comprehensive income for the current period is ¥18,509,389.16, down 46.0% from ¥34,335,329.36 in the previous period[25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 867,498,308.29, a decrease of 0.59% from the end of the previous year[7]. - Total assets as of September 30, 2025, amounted to ¥867,498,308.29, slightly down from ¥872,667,220.25 at the beginning of the period, a decrease of approximately 0.6%[20]. - Total liabilities decreased to ¥106,863,577.34 from ¥110,170,830.92, reflecting a decline of about 3%[20]. - Non-current assets totaled ¥306,227,243.18, down from ¥324,852,711.62, a decrease of approximately 5.8%[20]. - Inventory levels decreased to ¥39,640,778.12 from ¥44,779,230.07, a reduction of about 11.5%[19]. Cash Flow - Cash flow from operating activities for the current period is ¥69,076,293.49, compared to ¥73,855,724.26 in the previous period, indicating a decline of 6.5%[27]. - Cash inflow from investment activities is ¥853,948,042.86, an increase from ¥628,890,104.22 in the previous period, marking a growth of 35.7%[27]. - Cash outflow from investment activities is ¥931,432,771.04, up from ¥778,483,765.35 in the previous period, reflecting an increase of 19.6%[27]. - The net cash flow from investment activities is -¥77,484,728.18, an improvement from -¥149,593,661.13 in the previous period[27]. - The cash and cash equivalents at the end of the period amount to ¥125,582,982.32, down from ¥167,991,874.58 in the previous period, a decrease of 25.2%[28]. - The company reported a decrease in cash flow from financing activities, with a net cash flow of -¥20,571,047.54 compared to -¥27,381,218.60 in the previous period, showing an improvement of 25.5%[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 4,986[13]. - The largest shareholder, Huang Fan, holds 24.16% of the shares, totaling 16,429,650 shares[13]. - The second-largest shareholder, Xiang Bingyi, owns 20.25% of the shares, amounting to 13,770,000 shares[13]. - The total number of shares with limited sale conditions at the beginning of the period was 49,587,900, with 49,572,000 shares released from restrictions during the period[15]. - The company’s controlling shareholder and actual controller, Huang Fan, will change after the expiration of the joint action agreement on July 5, 2025[16]. - The company has a total of 27,829,387 shares that remain under lock-up conditions at the end of the reporting period[15]. - The number of shares held by the top ten shareholders accounts for a significant portion of the total shares, with Huang Fan and Xiang Bingyi being the most prominent[13]. - The company has no preferred shareholders or changes in preferred shareholder status reported[14]. - There are no shareholders participating in margin financing or securities lending activities[14]. - The company plans to release 49,572,000 shares for public trading after the lock-up period ends[16]. Expenses - Research and development expenses decreased by 32.01% to CNY 5,727,947.61, primarily due to a reduction in R&D personnel[11]. - Sales expenses increased by 50.15% to CNY 11,799,884.10, mainly due to higher compensation for sales staff[11]. Investment Income - Investment income rose by 110.87% to CNY 3,671,037.32, attributed to increased returns from financial products[11]. - The company reported a net investment income of ¥3,671,037.32, compared to ¥1,740,896.22 in the previous period, indicating an increase of approximately 110.5%[24]. - Cash received from investment redemption increased by 35.80% to CNY 851,457,122.75, reflecting higher amounts redeemed from financial products[11]. - Deferred income increased by 35.54% to CNY 18,054,679.60, mainly due to an increase in government subsidies related to assets[12]. - The company received government subsidies amounting to CNY 354,134.11 during the reporting period, contributing to its non-operating income[8].